Anders Svenningsson

Karolinska Institutet

Research Interests

Explore related searches

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (20)

Collaborators (8)

Joachim Burman

Uppsala University

Katharina Fink

Karolinska Institutet

Peter Vestergaard Rasmussen

Associate professor

Aarhus University

Kim Kultima

Uppsala University

Jonatan Salzer

Lecturer, Consultant neurologist

Umeå University

Jan Lycke

Consultant/Professor

Sahlgrenska universitetssjukhuset

Anna Fogdell-Hahn

Karolinska Institutet

Victoria M Leavitt

Columbia University Irving Medical Center

UNITED STATES

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Anders Svenningsson

Research Interests

Explore related searches

Contact this professor

Articles (20)

Collaborators (8)

Joachim Burman

Katharina Fink

Peter Vestergaard Rasmussen

Kim Kultima

Jonatan Salzer

Jan Lycke

Anna Fogdell-Hahn

Victoria M Leavitt

Make your next move.

Anders Svenningsson

Research Interests

Explore related searches

Contact this professor

Articles (20)

The number of apheresis procedures to treat immune-mediated neurological diseases is on the rise.

Orthostatic Tremor Is Evoked by Muscle Load Without the Need for Orthostatic Position

Comparison of CSF biomarkers in multiple sclerosis patients treated with natalizumab and rituximab

Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study

COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab.

Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study.

A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab.

Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy

Disease phenotype prediction in multiple sclerosis

Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort.

COVID-19 clinical outcomes and DMT of MS patients and population-based controls

Cerebral microvascular injuries in severe COVID-19 infection: progression of white matter hyperintensities post-infection

Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis

Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary

Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial

Metabolomics of Cerebrospinal Fluid from Healthy Subjects Reveal Metabolites Associated with Ageing

Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension

Perinatal Depression and Anxiety in Multiple Sclerosis: Treatable Distress

Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients

Collaborators (8)

Joachim Burman

Katharina Fink

Peter Vestergaard Rasmussen

Kim Kultima

Jonatan Salzer

Jan Lycke

Anna Fogdell-Hahn

Victoria M Leavitt

Make your next move.